Abstract
Summary Dengue, a major public health threat, is a viral infection spread by mosquitoes that can cause a range of symptoms from mild to life-threatening. Our study analyzed 19 years of data from two pediatric studies in children 2 to 17 years of age in Managua, Nicaragua. We aimed to understand how dengue severity varies with different serotypes of dengue virus (DENV1-4) and whether the child had a previous dengue infection. We found that DENV2 and DENV3 caused the most sever disease in children. DENV3 lead to sever outcomes in both primary (first-time) and secondary (repeat) infections, while DENV2 is particularly severe in secondary infections. These findings highlight the importance of a balanced dengue vaccine that can protect against all four virus strains, as current vaccines show varying effectiveness. Our research emphasizes the need for effective prevention and treatment strategies to manage dengue, particularly in regions where the virus is widespread.
Background Dengue virus, a major global health threat, consists of four serotypes (DENV1-4) that cause a range of clinical manifestations from mild to severe and potentially fatal disease.
Methods This study, based on 19 years of data from the Pediatric Dengue Cohort Study and Pediatric Dengue Hospital-based Study in Managua, Nicaragua, investigates the relationship of serotype and immune status with dengue severity. Dengue cases were confirmed by molecular, serological, and/or virological methods, and sudy participants 6 months to 17 years old were followed during their hospital stay or as ambulatory patients.
Results We enrolled a total of 15,266 participants, of whom 3,227 (21%) were positive for DENV infection. Of 2,630 cases with serotype result by RT-PCR, 557 corresponded to DENV1, 992 to DENV2, 759 to DENV3 and 322 to DENV4. Severe disease was more prevalent among secondary DENV2 and DENV4 cases, while similar disease severity was observed in both primary and secondary DENV1 and DENV3 cases. According to the 1997 World Health Organization (WHO) severity classification, both DENV2 and DENV3 caused a higher proportion of severe disease compared to other serotypes, whereas DENV3 caused the greatest percentage of severity according to the WHO-2009 classification. DENV2 was associated with increased odds of pleural effusion and low platelet count, while DENV3 was associated with both hypotensive and compensated shock.
Conclusions These findings demonstrate differences in dengue severity by serotype and immune status and emphasize the critical need for a dengue vaccine with balanced effectiveness against all four serotypes, particularly as existing vaccines show variable efficacy by serotype and serostatus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) grant numbers P01 AI106695 (EH) and R01 AI099631 (AB). The studies were supported by P01 AI106695 (EH), U01 AI153416 (EH), U19 AI118610 (EH), R01 AI099631 (AB), U54 AI65359 (Barbour; subcontract AB), and BAA-NIAID-DAIT-NIHAI2009061 (Loeb; subcontract AB) from NIAID/NIH, and the the Pediatric Dengue Vaccine Initiative grant VE-1 (EH) and the FIRST grant (EH) from the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics IRB of the Nicaraguan Ministry of Health (Protocol #CIRE-09/03/07-008.Ver24, CIRE-01/10/06-13.ver8) and the University of California Berkeley Committee for the Protection of Human Subjects (Protocols 2010-09-2245, 2010-06-1649) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵a Current affiliation: ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain Section: Vector-borne Diseases or Global Health and Neglected Tropical Diseases
Results have been updated to include up to May 2024.
Data Availability
After securing approval from the UC Berkeley Committee for the Protection of Human Subjects, individual data for figure reproduction can be shared with external researchers. For data access arrangements, please contact E.H. at eharris{at}berkeley.edu or the CPHS at ophs{at}berkeley.edu. Standard data transfer agreements govern all data used in this study.
https://github.com/jgjuarez/Narvaez_Dengue_Clinical_Severity
